Uroflam

Quick links to important sections

Uroflam

Method of action: Analgesic, Analgetic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uroflam

Quick Facts

Property Description
Active Ingredient Phenazopyridine hydrochloride
Form Oral tablet
Pharmacological Class Urinary analgesic
General Purpose Symptomatic relief of pain, burning, urgency
Origin Synthetic azo dye

What Type of Medicine is Uroflam (Phenazopyridine)?

Uroflam is a single-ingredient medicinal product whose active component is Phenazopyridine hydrochloride, a substance that is clinically recognized for its localized pain-relieving effects in the urinary tract. It is classified as a urinary analgesic and is included among the miscellaneous genitourinary tract agents.

Administered as an oral tablet, Phenazopyridine is generally intended for symptomatic relief rather than addressing the underlying cause of irritation, such as a bacterial infection. Its primary role is that of an adjuvant medicine, often used alongside other therapies to help manage the painful symptoms of discomfort, burning, and urgency. Phenazopyridine has an established use for easing the symptoms of irritation in the lower urinary system.


Composition and Origin: The Role of the Azo Dye

The foundation of the drug is the Phenazopyridine hydrochloride compound, which is synthetic in origin and derived from the azo dye chemical class. This active ingredient is formulated into an oral tablet alongside various standard solid excipients required for manufacturing.

A key differentiating feature is that the compound is designed for rapid excretion by the kidneys, concentrating its effects within the urine. This chemical characteristic ensures the substance delivers its effect precisely to the urinary tract lining. The presence of this azo dye inevitably causes a distinctive and harmless orange-to-red discoloration of the urine during the course of its use, which serves as a visible confirmation of the drug's activity in the system.


General Purpose and Core Analgesic Effect

The general purpose of Uroflam is solely to provide symptomatic relief by mitigating the discomfort caused by irritation. It achieves this benefit through a topical analgesic action.

Phenazopyridine delivers a localized anesthetic effect directly onto the lining (mucosa) of the bladder and urethra as it is concentrated and excreted in the urine. This action specifically reduces the sensitivity of irritated nerve endings in the urinary tract, without affecting pain perception elsewhere in the body. By providing this direct, numbing effect, the medicine effectively mitigates the painful symptoms of burning, increased urgency, and general discomfort that originate in the lower urinary system.

Regulatory References

  1. Phenazopyridine - MedlinePlus Drug Information (NLM/NIH)
  2. Phenazopyridine - MedlinePlus Drug Information

What side effects are possible with Uroflam?

Possible side effects and safety information

The safety profile of Uroflam (Phenazopyridine hydrochloride) details potential adverse reactions and specific constraints documented in regulatory labeling. As an azo dye, the medication causes a reddish-orange discoloration of the urine and feces, which is an expected, inherent property and not an adverse reaction. This discoloration may also cause staining of contact lenses.


Adverse Reaction Categories

Adverse reactions are reported without standard frequency classifications in core U.S. regulatory documents, though some reactions are noted as occurring usually at overdosage levels. Reported effects are typically categorized by the organ system involved:

System-Organ Class Specific Adverse Reactions (as listed)
Gastrointestinal Nausea, vomiting, diarrhea, gastrointestinal disturbance
Nervous System Headache, visual disturbances
Dermatologic/Immune Rash, pruritus, anaphylactoid-like reaction, discoloration of skin/sclera
Hematologic/Hepatobiliary Methemoglobinemia, hemolytic anemia, jaundice, hepatic toxicity

Serious Safety Considerations

Serious adverse reactions documented in regulatory sources include Methemoglobinemia, Hemolytic Anemia, and Renal and Hepatic Toxicity, which are often linked to overdosage or pre-existing organ impairment. The regulatory classification also includes the note that the drug is reasonably anticipated to be a human carcinogen based on evidence from animal studies.


Population-Specific Safety Constraints

Phenazopyridine is contraindicated in patients with renal insufficiency and severe liver disease. Caution is advised in older adults, where a decline in renal function is common, and in individuals with G-6-PD deficiency, who are susceptible to oxidative hemolysis. A yellowish tinge of the skin or sclera may indicate drug accumulation due to impaired excretion, which requires discontinuation of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

This section summarizes the officially documented manifestations and required emergency actions for an overdose of Uroflam (Phenazopyridine hydrochloride) as stated in regulatory prescribing information.

Documented Clinical Manifestations:

A massive, acute overdose is strongly associated with methemoglobinemia, a potentially life-threatening condition where the blood's oxygen-carrying capacity is impaired. Clinical signs of this severe event may include cyanosis (bluish discoloration of the skin). Chronic overdosage can lead to oxidative Heinz body hemolytic anemia and signs of systemic accumulation, such as jaundice (yellowing of the skin or eyes).

Systemic Toxicities and Risk Factors:

Regulatory documents report the potential for severe damage to the kidneys (renal toxicity and occasional failure) and liver (hepatic impairment). The risk of toxic reactions is heightened in patients with existing impaired renal function, including elderly individuals, and those with a red blood cell enzyme deficiency known as G-6-PD deficiency.

Mandatory Emergency Actions:

Immediate medical attention is required for any suspected overdose. Official guidance mandates contacting a regional poison control center or going to the local emergency room at once. Emergency services must be called if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Treatment is generally symptomatic and supportive. The specific antidote documented for methemoglobinemia is intravenous methylene blue.

Therapeutic Uses of Uroflam

Quick Facts on Uroflam

  • Primary Therapeutic Use: Helps manage muscle spasms of the urinary tract.
  • Indicated for Symptom Relief: May offer relief from discomfort associated with painful urination (dysuria).
  • Additional Supported Uses: Supports a reduction in urinary urgency, frequency, and excessive urination at night (nocturia) in appropriate individuals.

What Uroflam Treats: Main Uses and Benefits

Uroflam is a therapeutic agent indicated for the management of muscle spasms within the urinary tract. Its primary purpose is to address symptoms that may occur as a result of certain bladder, urethra, or prostate conditions. The medication may help provide relief from the associated discomfort and pain.

Individuals prescribed this treatment may find it supports a reduction in the urge to urinate frequently, which is a key symptom of urinary tract irritation. It is also indicated to assist in alleviating urinary urgency and the need to urinate excessively during nighttime hours.

This agent is used to help manage these urinary symptoms, but it is important to understand it is not an antibiotic and does not treat underlying infections. A healthcare provider determines the proper use and indication for each patient.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Population Eligibility for Uroflam

Category Regulatory Status / Restriction
Populations for whom use is allowed Adults experiencing symptomatic discomfort of the lower urinary tract [1.1] [2.4]. Use is compatible with antibacterial therapy [1.1].
Populations for whom use is contraindicated Patients with renal insufficiency (impaired kidney function) or severe liver disease [1.1] [1.4] [3.3]. Use is also prohibited in patients with known hypersensitivity to the active ingredient [1.1].
Age-related eligibility rules Pediatric: Safety and effectiveness have not been established in the pediatric population (children) [1.1]. Geriatric: Caution is advised due to the risk of drug accumulation linked to age-related decline in renal function [1.2] [2.5].
Pregnancy and lactation eligibility Pregnancy: Classified as Pregnancy Category B. Use is restricted to instances where the benefit clearly outweighs the potential risk [1.1] [2.4]. Lactation: Use is not recommended, as it is unknown if the drug or its metabolites are excreted into human milk [1.1] [2.4].
Eligibility-related restrictions Use with an antibacterial agent must not exceed 2 days [1.4] [2.4]. Use is also advised with caution in patients with G-6-PD deficiency [1.2] [3.3].

Connection to the Overall Eligibility Profile

Regulatory documents define strict boundaries for Uroflam use, primarily based on the drug's rapid excretion by the kidneys. This establishes absolute non-eligibility for patients with impaired renal or severe hepatic function. Eligibility is further restricted by a mandatory time limit when treating a urinary infection and by the status of use not established in children. The final decision to discontinue the drug is required if a yellowish tinge of the skin or eyes appears, indicating drug accumulation due to impaired renal excretion [1.2] [1.4].

What should I know about interactions with other medicines?

Uroflam Interactions with other medicines and products

The official regulatory information for Uroflam (Phenazopyridine hydrochloride) focuses on mandated time limits, interference with diagnostic procedures, and cautions related to patient-specific conditions, rather than common drug-to-drug interactions.


1. Restriction on Co-administration Duration

When Uroflam is used at the same time as an antibacterial agent (such as for a urinary tract infection), official prescribing information mandates that administration must not exceed 2 days. This restriction is based on the lack of official evidence that continued combined use provides greater therapeutic benefit than the antibacterial agent alone.

2. Interference with Laboratory Tests

As a synthetic azo dye, Uroflam is officially documented to interfere with the results of certain laboratory tests. Due to its intense color, it can compromise the accuracy of urinalysis tests that rely on colorimetric, spectrophotometric, or fluorometric methods. Altered results may occur for tests measuring substances such as bilirubin, ketones, and glucose.

3. Population-Specific Interaction Cautions

No specific drug-drug combinations are formally contraindicated. However, the risk of drug accumulation and toxicity is significantly increased in patients with impaired renal function or severe liver disease. This is an official, population-specific caution that restricts use due to impaired drug clearance. Cautious use is also advised for individuals with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency.

4. Undocumented Pharmacokinetic Interactions

Official regulatory labels indicate that drug-drug interactions involving metabolic pathways, such as the cytochrome P450 (CYP) enzyme system, or drug transporters have not been systematically studied and no significant interactions of this type are officially reported.

Mechanism of Action

Targeted Numbing via Peripheral Nerve Membrane Stabilization

Uroflam exerts its action through a localized topical anesthetic mechanism, primarily targeting the sensory nerve endings within the mucosa of the lower urinary tract (bladder and urethra). Upon contact, the compound functionally stabilizes the neuronal membranes, resulting in a direct membrane stabilization effect that raises the threshold needed to initiate a nerve impulse. This interruption of the peripheral nociceptive signaling pathway physiologically suppresses the transmission of afferent sensory signals originating from the affected tissue.


Mechanism Driven by Excretion-Dependent Activity

The drug's activity is intrinsically linked to its rapid renal excretion, which concentrates the active substance directly in the urine. This process provides a highly site-specific targeting mechanism, ensuring the active compound is delivered in high concentration precisely to the urothelial lining. The physiological consequence of this excretion-dependent activity is a strictly localized-only effect, wherein the mechanism modulates afferent sensory responses in the lower urinary system, distinct from central nervous system (CNS) pain modulation.

Dosage and Administration Information

How to Use Uroflam (Flavoxate) — Administration Guidelines

Uroflam, containing the active ingredient Flavoxate, is administered via the oral route using a tablet dosage form. Adherence to the prescribed regimen is crucial for its proper use.

Administration Scope Instruction
Dosing Regimen Adults and children 12 years and older typically take 100 mg to 200 mg per dose.
Frequency The prescribed dose is usually taken three or four times a day.
Timing Relative to Meals While it can be taken with water, the medicine may be taken with food or milk if a prescriber recommends it to lessen stomach upset.
Missed Dose If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid doubling the dose.
Pediatric Use The medicine is not recommended for children under 12 years of age, as safety and efficacy have not been established in this age group.

Procedural Structure:

  1. Take the prescribed dose (one or two 100 mg tablets) orally with water.
  2. Administer the dose according to the three or four times daily frequency established by the healthcare provider.
  3. Do not take the medicine more often or for a longer time than directed by the prescriber.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uroflam

Evidence for Symptomatic Relief of Lower Urinary Tract Discomfort

Research has explored Uroflam in studies examining acute symptoms such as pain, burning, and the frequent urge to urinate that accompany irritation in the lower urinary tract. Research on Uroflam evaluating patterns related to subjective symptoms has primarily involved short-term randomized controlled trials (RCTs), where the medicine was compared to a placebo or to other standard care. These trials mostly included adult females. Studies monitored outcomes describing episodic or acute changes, particularly the degree of pain upon urination (dysuria).

Findings describe patterns observed in the studies related to measurements of subjective discomfort. Research provides insight into short-term changes and helps contextualize how patients reported their experience during episodes of heightened symptom activity. The evidence is limited, as the research structure relies significantly on historical clinical experience and older trials. Follow-up durations were limited, meaning the data show patterns related only to very short-term use, typically three days or less.


Research on Duration of Use and Long-Term Outcomes

Studies conducted on Uroflam primarily explore short-term symptom changes, focusing on temporary periods of observation. The typical follow-up durations in clinical trials have been limited to 72 hours or less. This short-term focus is consistent with the drug’s role as a symptomatic agent used during the initial phase of symptomatic irritation.

Consequently, there is limited information for long-term outcomes or sustained patterns of symptom change. Research does not determine whether an individual will experience sustained symptom change or how the medicine affects symptoms over an extended period. Long-term effects are not fully established, meaning the existing evidence base does not provide insight into outcomes beyond the defined, short-term treatment intervals.


Known Research Gaps and Areas of Scientific Uncertainty

A key research limitation is the modest size and limited number of recent clinical trials. Much of the knowledge related to Uroflam is based on historical evidence and clinical experience that predate current, rigorous reporting standards. Comparative evidence is lacking, meaning there are few studies that directly compare Uroflam to other non-antibiotic treatments for the symptoms it addresses.

Key Studies & References

  1. Label: PHENAZOPYRIDINE HYDROCHLORIDE tablet - DailyMed - NIH (Clinical Pharmacology and Indications sections)
  2. Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI) (NCT01650051)
  3. Safety analysis of long-term phenazopyridine use for radiation cystitis (Example of research on extended use and safety in special populations)

Frequently Asked Questions (FAQ)

Common questions about Uroflam (FAQ)

Q: What is the main difference between Uroflam and other common urinary relief medicines?

A: Uroflam is officially classified as a urinary analgesic and is chemically a synthetic azo dye. Its key function is to act as a localized anesthetic, which means it numbs the sensory nerve endings directly on the lining of the urinary tract (bladder and urethra).

Q: How quickly should I expect to feel a change after starting Uroflam?

A: Because the active component is rapidly concentrated and excreted by the kidneys, its symptomatic effect is generally described as providing prompt relief from burning and pain.

Q: Is it possible to take Uroflam with common pain relievers like ibuprofen or acetaminophen?

A: Official regulatory information does not currently list severe or serious direct drug-drug interactions between Phenazopyridine and common over-the-counter pain relievers like ibuprofen or acetaminophen. Patients should review all current medications with a healthcare professional.

Q: Are there any specific foods or drinks that should be avoided while using Uroflam?

A: Official documents do not list any specific foods or drinks that are contraindicated or must be avoided while using Uroflam. Regulatory documents mention that taking the medicine with food or milk may lessen stomach upset.

Q: Is Uroflam known to be addictive?

A: Official regulatory labels indicate that no information is available regarding Uroflam’s potential for drug abuse or its likelihood to cause dependence. The drug is not classified as a controlled substance.

Q: How long does the effect of one dose of Uroflam usually last?

A: The full duration of the symptomatic effect has not been fully determined through pharmacokinetic studies. However, the typical prescribed dosing frequency of three to four times a day suggests the relief is intended to last for several hours between doses.

Q: Is Uroflam available over the counter, or is it prescription only?

A: The active ingredient in Uroflam, phenazopyridine hydrochloride, is generally available in both prescription and over-the-counter (OTC) forms. The availability often depends on the specific dosage strength regulated in a given region.

Q: Can people who are allergic to sulfa drugs take Uroflam?

A: Uroflam is chemically an azo dye, which is a different compound classification than sulfonamide ('sulfa') drugs. Patients with a known history of drug hypersensitivity should review their medical history with a healthcare provider.

Q: Does taking Uroflam interfere with driving or operating machinery?

A: The official label does not contain a direct warning against driving. However, side effects such as dizziness and visual disturbances have been reported. Patients experiencing these side effects should not engage in activities requiring mental alertness, such as driving or operating machinery.

Q: Does Uroflam make you gain or lose weight?

A: Unspecified weight gain has been listed as a rare potential side effect in regulatory documents. This symptom is generally reported in regulatory documents when accompanying signs of fluid retention.

Q: How long after stopping Uroflam will it be completely out of my system?

A: The drug is rapidly excreted by the kidneys, and its elimination is relatively quick. Its full pharmacokinetic properties are not completely determined in humans, but its elimination is relatively quick, with pharmacokinetic data suggesting a half-life of several hours.

Q: Is there a generic version of Uroflam available?

A: Yes, official regulatory records confirm that the active ingredient, phenazopyridine hydrochloride, is widely available as a generic medication.

Q: Does Uroflam have any interaction with alcohol?

A: Official regulatory sources state that Uroflam is not known to have a direct chemical interaction with alcohol. However, alcohol can sometimes irritate the bladder, which may potentially worsen the urinary symptoms the drug is intended to relieve.

Q: Does Uroflam cause drowsiness or make you tired?

A: Official documents report that feeling tired, weak, or very sleepy has been noted as a potential side effect. These effects are often reported in connection with more serious, but rare, blood-related adverse reactions like methemoglobinemia.

Q: I've seen Uroflam mentioned for bladder spasms—is that its only use?

A: The primary and official purpose of Uroflam is to provide symptomatic relief for irritation in the lower urinary tract, including pain, burning, urgency, and frequency. This generalized relief often covers discomfort associated with bladder spasms, but it is not its sole indicated use.

Q: I read Uroflam can cause a headache—how common is this side effect?

A: Headache is listed in official sources as a reported adverse reaction of the drug. Regulatory documents, however, typically do not provide standard frequency categories, such as 'common' or 'rare,' for most of the reported side effects.

Q: Can people with diabetes use Uroflam?

A: There are no official contraindications for people with diabetes in the regulatory information. However, official product information indicates that the drug can interfere with the results of certain urine tests that measure substances like glucose (sugar).

Q: What is the general safety classification of Uroflam by regulators?

A: Uroflam is officially classified as a urinary analgesic. Official regulatory materials note that based on evidence from long-term animal studies, the drug is listed as 'reasonably anticipated to be a human carcinogen.'

Q: Is Uroflam known to cause dizziness?

A: Official product information confirms that dizziness is a reported side effect of Uroflam. This can sometimes include vertigo (a spinning sensation) and is particularly noted in cases related to serious adverse reactions.

Q: Does Uroflam help with nighttime urination?

A: The drug is indicated for relieving symptoms like urinary urgency and frequency. Relief from these symptoms can help manage the discomfort associated with frequent nighttime urges (nocturia).

Q: Are the side effects of Uroflam more likely in older patients?

A: Regulatory documents include a specific caution for older patients due to the common age-related decline in kidney function. The potential for drug accumulation may lead to an increased risk of toxic reactions and serious side effects.

How should Uroflam be stored and disposed of?

How to Store and Dispose of Uroflam (Phenazopyridine)

The storage and disposal of Uroflam (Phenazopyridine) must strictly follow official regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature).
Protection Keep from freezing and store away from excess heat, moisture, and direct light.
Container Keep medication in the tightly closed, original container.
Child Safety Must be stored strictly out of the reach of children.

Disposal Instructions

Do not keep outdated or unused medicine. Disposal should follow guidance from a pharmacist or healthcare professional, often involving a drug take-back program. If a take-back program is unavailable, follow general household disposal guidelines by mixing the medicine with an undesirable substance before discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uroflam found in:

A-Z Index: